Reishi is the most revered mushroom in Traditional Chinese Medicine — and one of the most difficult to evaluate through a modern clinical lens. Three thousand years of use as a Shen tonic (calming the spirit) and longevity support create an expectation that the evidence base cannot fulfill. Th...'s immune response, in particular on T-cells." Quality was rated low to very low across all outcomes. No trial measured survival. The review explicitly noted that reishi might have better effects when combined with conventional cancer treatment rather than used alone — but this also requires more research.
For sleep, there are essentially no RCTs. The calming effect is attributed to triterpenes and possible GABA-A receptor modulation, but this comes from in vitro and animal data, not human sleep trials. If you're choosing reishi specifically for sleep, you're betting on tradition and mechanism, not clinical validation. Magnesium glycinate, ashwagandha, and L-theanine all have stronger sleep trial data.
The immune evidence is slightly better but still limited. Several small trials show increased NK cell activity and altered cytokine profiles during chemotherapy, but sample sizes are tiny and results are inconsistent. The Gao 2003 trial (n=134) is sometimes cited for immune enhancement in cancer patients, but it was not placebo-controlled.
Practical considerations: quality varies enormously. Look for products that specify beta-glucan and triterpene content. Hot-water extracts emphasize beta-glucans; dual extracts capture both. Most reputable brands (Real Mushrooms, Nootropics Depot, Host Defense) provide certificates of analysis. Avoid products that don't specify extraction method or standardization.
The honest framing matters here. Reishi is a traditional tonic with plausible mechanisms and a long safety history, but the modern clinical evidence is thin. It's reasonable as part of a broad wellness protocol with modest expectations. It's not a substitute for evidence-based interventions for sleep, cancer, or immune deficiency.
Keystone references: Klupp et al. 2015 (Cochrane Database Syst Rev, PMID 26068975 — cancer adjuvant Cochrane review); Gao et al. 2004 (J Med Food, PMID 15830302 — quality of life in breast cancer); Gao et al. 2005 (J Altern Complement Med, PMID 16314588 — phase I safety in advanced cancer).